Premature Rupture of Mambrane and Unfavourable Cervix

Overview

The paucity of published data concerning the issue of mechanical labor induction in the setting of Term PROM has led us to undertake the present clinical trial. This study is designed to compare the efficacy and safety of the standard Oxytocin induction protocol with the double-balloon catheter device with concurrent oxytocin administration in patients with Term PROM and unfavorable cervical conditions.

Full Title of Study: “Comparison Between the Use of Standard Oxytocin Induction Protocol and the Double-balloon Catheter Device With Concurrent Oxytocin”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2014

Detailed Description

This will be a prospective randomised trial. Two hundred pregnant women with term PROM and an unfavourable cervix (Bishop Score ≤ 4) are expected to be entered into the study (see statistical analysis below). All eligible women will be presented with the study protocol by a study coordinator. Women interested in participating will read and sign the informed consent. Subsequently, the following screening medical procedures will be completed: medical and gynecological history, physical and vaginal examination, ultrasonography to: (i) Confirm fetal vertex presentation, (ii) Exclude placenta previa and (iii) Assess cervical length and posterior cervical angle. (iv) Asses bio-physical profile score A non-stress test will be performed in order to monitor: 1. The fetal heart pattern for the presence or absence of decelerations and 2. The presence of uterine contractions. All women will undergo a pelvic examination by a staff member to obtain an initial Bishop score. If the patient will be determined eligible for study entry, and following the informed consent, randomisation into the following groups will take place: GROUP 1: Oxytocin infusion alone (Standard Protocol). GROUP 2: insertion of the double balloon device and concurrent oxytocin administration. GROUP 3: Expectant management

Interventions

  • Device: COOK RIPENENIG BALLOON+PITOCN
    • GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
  • Drug: PITOCIN
    • : Oxytocin infusion alone (Standard Protocol
  • Other: double balloonand oxytocin
    • balloonand oxytocin
  • Other: ballon and oxytocin
    • double- balloon catheter device with concurrent oxytocin
  • Procedure: double balloonand and oxytocin
    • balloon catheter device with concurrent oxytocin

Arms, Groups and Cohorts

  • Experimental: GROUP 1: Oxytocin infusion alone
    • GROUP 1: Oxytocin infusion alone
  • Experimental: double balloonand oxytocin
    • insertion of the double balloon and oxytocin

Clinical Trial Outcome Measures

Primary Measures

  • PPROM/PROM to delivery interval
    • Time Frame: 3year
    • Time from rupture of mambrane to delivery From hospitalization until delivery

Participating in This Clinical Trial

Inclusion Criteria

1. Diagnosed to be pregnant with PROM at > 34 week 2. Found to have a Bishop score of 4 points or less. 3. Diagnosed as having a singleto 4. Willingness to comply with the protocol for the duration of the study. 5. Have signed an informed consent. Exclusion Criteria:

1. Any contraindication for a vaginal deliver 2. Regular uterine contractn 3. Evidence of chorio-amonitis 4. Previous cesarean section or presence of any uterine scar. 5. Suspected placental abruption or presence of a significant hemorrhage. 6. Non-reassuring fetal statu

Gender Eligibility: Female

Minimum Age: 16 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Hillel Yaffe Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Elad Mei-Dan, DR, Principal Investigator, Hillel Yaffe Medical Center
  • Overall Contact(s)
    • Elad Mei-Dan, Dr, 972-4-6188243

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.